Details for Patent: 7,452,872

Which drugs does patent 7,452,872 protect, and when does it expire?

Patent 7,452,872 protects GIAZO and COLAZAL and is included in two NDAs.

Protection for COLAZAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twelve countries.

Summary for Patent: 7,452,872

Title:	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Abstract:	A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
Inventor(s):	Johnson; Lorin (Palo Alto, CA)
Assignee:	Salix Pharmaceuticals, Inc. (Morrisville, NC)
Application Number:	11/835,897
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,452,872
Patent Claim Types: see list of patent claims	Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,452,872

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Valeant Pharms Intl	GIAZO	balsalazide disodium	TABLET;ORAL	022205-001	Feb 3, 2012		DISCN	Yes	No						TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
Valeant Pharms Intl	COLAZAL	balsalazide disodium	CAPSULE;ORAL	020610-001	Jul 18, 2000	AB	RX	Yes	Yes					Y

International Family Members for US Patent 7,452,872

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006282865
Australia	2007322362
Brazil	PI0615195
Brazil	PI0717859
Canada	2620091